Abstract
Basal cell carcinoma (BCC) is the most common malignant tumor among fair-skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow-up of patients with basal cell carcinoma.
Author supplied keywords
- antineoplastic agent
- article
- basal cell carcinoma
- cancer radiotherapy
- cancer recurrence
- cancer surgery
- cryosurgery
- cyclooxygenase 2 inhibitor
- diclofenac
- drug delivery system
- electrochemotherapy
- erbium YAG laser
- fluorouracil
- follow up
- geriatric patient
- histopathology
- human
- imiquimod
- ingenol mebutate
- low level laser therapy
- nicotinamide
- photodynamic therapy
- practice guideline
- radiation dermatitis
- recurrence risk
- retinoid
- sonedigib
- tumor volume
- unclassified drug
- vismodegib
Cite
CITATION STYLE
B.M., L., P., B., A., B., A., B., G.F., B., T., D., … S., G. (2019). S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow-up. JDDG - Journal of the German Society of Dermatology, 17(2), 214–230. Retrieved from http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L626401730 http://dx.doi.org/10.1111/ddg.13755
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.